USFDA Clears Piramal Pharma's Ahmedabad Facility for High-End Analytical Services

The US Food and Drug Administration (USFDA) conducted a pre-approval inspection of Piramal Pharma's PPDS Ahmedabad facility from July 10 to July 12, 2024. The inspection was successfully completed without any form 483 observations, resulting in a "no action indicated" designation. This comprehensive inspection's success will now allow the company to offer high-end analytical capabilities to customers for their clinical and commercial batches from an FDA-approved site. Piramal Pharma (PPL) provides a portfolio of differentiated products and services through its end-to-end manufacturing capabilities across 17 global facilities and a distribution network spanning over 100 countries. PPL encompasses Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, which sells over-the-counter products.